Home » Investment in Middle East »

|| Middle East Business of a Giant Pharma Acquired for $23.2 million

Middle East Investors PharmaIn a deal between two multi-billion dollar companies, a part of the Middle East business of one large pharmaceutical giant changed hand to another giant pharma.

GlaxoSmithKline plc (GSK), the world's third largest pharmaceutical company, today announced that it has acquired the branded generics business of Bristol Myers Squibb (BMS) in Lebanon, Jordan, Syria, Libya and Yemen for a cash consideration of $23.2m.

The reason: "extending its product portfolio in the Middle East and North Africa and accelerating growth in emerging markets". Developed markets are quiet and everyone wants a part of growth in emerging markets like the Middle East. (BMS will continue to supply the products acquired today until 2011 when it is anticipated that manufacture will transfer to GSK’s plant.)

Previous Post: Silicon Valley company acquired by Arabic language specialist Sakhr Software
Next Post: Presentation - Implications of a PE/VC investment on a company

|| About Us

Established in 2007, DubaiBeat.com provides insight, analysis and research on Middle East investors.

We cover different asset class investors like private equity, venture capital, hedge funds and real estate investors from the Middle East and broader MENA region.

|| Subscribe

Copyright 2007-2016 DubaiBeat.com    Sitemap  |  Terms  |  Privacy Policy

Follow us: RSS Feed   Facebook    Twitter